No Data
No Data
RedHill Biopharma Announced The Placement Of Low-dose Rifabutin-triple Therapy, Talicia, As An Empirically-prescribed First-line Option For Helicobacter Pylori Infection In The Newly Published American College Of Gastroenterology Clinical Guideline
RedHill Biopharma Announces ADS Ratio Change
RedHill Biopharma Regains Compliance With Nasdaq
Redhill Biopharma Announced The Publication Of Data, In Journal Microorganisms, From The Phase 2/3 Study Of Opaganib In Covid-19 Pneumonia That Showed 62% Reduction In Covid-19 Mortality
Express News | Redhill Biopharma H1 EPS $(0.00) Down From $0.04 YoY, Sales $2.57M Down From $5.39M YoY
RedHill Biopharma Cash Balance of $8.2 M as of June 30 >RDHL
No Data